广济药业(000952.SZ)：预计2025年净亏损3.99亿元-5.18亿元

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) expects a net profit attributable to shareholders of -518 million to -399 million yuan for 2025, compared to -295.29 million yuan in the same period last year, indicating a continued operational loss due to intensified market competition and low product prices [1] Group 1: Financial Performance - The company anticipates a net profit of -527.5 million to -408.5 million yuan after deducting non-recurring gains and losses [1] - The previous year's net profit was -295.29 million yuan, highlighting a worsening financial outlook [1] Group 2: Operational Challenges - The company is facing ongoing operational losses due to prolonged low sales prices of its main products and insufficient capacity utilization [1] - Several subsidiaries have not shown effective improvement in their operational status, continuing to incur losses [1] Group 3: Asset Impairment - There are significant signs of asset impairment due to insufficient production line operation rates and declining market prices [1] - The company plans to make impairment provisions for assets showing signs of impairment, with the final impairment amount to be determined by professional assessments and audits [1]